What Does MIT Mean in Kratom Products?
MIT is shorthand for mitragynine in the Kratom Paradise catalog. It appears on product names, selector values, and submitted-sample documents. The abbreviation helps identify a product family, but it does not turn every number beside it into the same kind of measurement.
Compare current MIT formats
Browse MIT chewable tablets, MIT 90% extract powder, or the complete standard and bulk MIT collection. Use MIT Tablets vs MIT Extract Powder to compare format, package, and report scope.
The most reliable way to read an MIT listing is to understand both the pharmacology and the fields: mitragynine is psychoactive, while product format, submitted product-line name, labeled milligram option, laboratory result, net weight, tablet count, flavor, and sample identifier describe different parts of the product record.
What people mean when they ask what MIT does
MIT means mitragynine, the most abundant psychoactive alkaloid usually measured in kratom leaf. Receptor studies show mu-opioid activity, and controlled human research shows measurable mitragynine and 7-OH concentrations after oral kratom consumption.
Mitragynine is not effect-equivalent to concentrated 7-OH, and an MIT label cannot promise one subjective result. Concentration, frequency, tolerance, metabolism, and other substances change the experience, while regular use can involve unwanted effects and dependence.
That is why the number beside MIT needs a basis. A person is not comparing abstract typography; they are comparing potentially meaningful alkaloid exposure. Clear milligram, percentage, count, weight, sample, and report fields help prevent category errors even though they cannot predict an individual's experience.
MIT is not a kratom strain name
Traditional catalog names such as Green Maeng Da, Red Bali, White Borneo, or Gold Bali belong to the botanical powder and leaf-filled capsule lanes. MIT identifies mitragynine-related labeling in a different catalog lane. A product can therefore be MIT-labeled without belonging to a red, green, white, or geographic strain family.
Six fields that should not be collapsed
| Field | Current catalog example | Read it as |
|---|---|---|
| Product-line label | MIT 90% mitragynine | The name of the current extract-powder line |
| Reported laboratory result | 87.01% mitragynine (870.12 mg/g) | The measured result for the identified submitted sample |
| Labeled milligram option | 150mg MIT | The tablet product-line label; compare it with the separate finished-tablet report |
| Net weight | 0.5g through 1kg | The quantity of extract powder in the selected package |
| Tablet count | 5 through 5,000 tablets | The number of units in the selected tablet package |
| Sample identifier | SD260715-011 (142956) / DD00126B(15) | The submitted concentrate sample described by the current powder report |
Product-line label and measured result are separate
The current MIT 90% extract-powder listings reference report DD00126B(15), sample ID SD260715-011 (142956). Its analytical table reports 87.01% mitragynine (870.12 mg/g) for the submitted concentrate sample. The 90% wording remains the product-line label; it is not a transcription of the measured result.
The full record matters. A product-line name should not be rewritten as though it were the laboratory result, and one submitted-sample report should not be expanded into an assurance about every size, packaged unit, or future lot.
No conversion or equivalency is implied
A labeled 150mg MIT option is not presented as equivalent to the MIT 90% extract-powder line. Net weight does not equal tablet count. A sample result does not establish a serving. Flavor does not create a new concentration claim. These fields can be recorded together, but they should not be mathematically converted without verified product information that expressly supports the comparison.
MIT and 7-hydroxymitragynine are different terms
Mitragynine and 7-hydroxymitragynine are distinct alkaloid terms. The store's 7-OH vs Kratom vs MIT page explains the category language in more detail. The current extract reports state that 7-hydroxymitragynine was ND at the laboratory's stated reporting threshold for the submitted samples they describe. That result is not a global claim about every tablet, flavor, package, or future lot.
Federal context must also remain precise. FDA states that there are no FDA-approved kratom drug products and that kratom is not lawfully marketed as a dietary supplement or conventional-food additive. HHS and FDA's July 2026 materials distinguish the enhanced 7-OH scheduling action from natural leaf kratom, but that distinction is not federal approval of Kratom Paradise tablets or extracts. See FDA and Kratom and the July 2026 HHS/FDA announcement.
Where each follow-up question belongs
- For format selection: MIT Products Guide.
- For current extract report links: MIT Product Documents & COA Center.
- For laboratory abbreviations and units: How to Read a Kratom Lab Report or COA.
- For batch, lot, and sample matching: Batch, Lot & Sample ID Guide.
- For current product options: MIT Products.
MIT terminology FAQ
Is MIT a kratom strain?
No. It is used here as shorthand for mitragynine in a distinct product-labeling lane.
Does a 150mg MIT tablet label equal a 90% extract-powder label?
No. The tablet milligram label and the extract-powder percentage label identify different product formats and are not presented as equivalent.
Is MIT the same term as 7-OH?
No. Mitragynine and 7-hydroxymitragynine are distinct alkaloid terms. Product-specific claims require product-specific evidence.
Label and catalog education only; no medical or legal advice, serving guidance, or product approval is provided.